logo
Share SHARE
FONT-SIZE Plus   Neg

Sanofi Says FDA Oks Auvi-Q For Patients With Life-threatening Allergic Reactions

Sanofi (SNY: Quote) said the FDA has approved Auvi-Q (epinephrine injection, USP) for the emergency treatment of life-threatening allergic reactions in people who are at risk for or have a history of anaphylaxis. Auvi-Q is the first-and-only compact epinephrine auto-injector with audio and visual cues that guide patients and caregivers step-by-step through the injection process.

Sanofi US licensed the North American commercialization rights to Auvi-Q from Intelliject, Inc., which has retained commercialization rights for the rest of the world.

"With this FDA approval, Auvi-Q will become the first-and-only epinephrine auto-injector that talks users through each step of the injection process," said Bryan Downey, Vice President, Auvi-Q, Sanofi US. "We are confident that Auvi-Q will provide the up to six million Americans at risk for anaphylaxis and their caregivers an easy-to-use, compact option with unique features to help manage a life-threatening allergic reaction."

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
France is reported to be considering new laws that will make Internet companies like Google and Facebook liable for social media posts inciting terrorism. The FCC has warned Marriott and other hotel chains to stop the "disturbing trend" of illegally blocking guests' private wi-fi. Marriott, which was fined $600,000 for blocking personal hotspots in hotel rooms and conference spaces, recently stopped the practice after a storm of criticism on social... Apple Inc. said Tuesday after the markets closed that its first quarter profit rose 38% from last year, driven by all time record revenue from iPhone and Mac sales as well as record performance of its App Store. The company's quarterly earnings per share also breezed past Wall Street expectations as did its quarterly sales.
comments powered by Disqus
Follow RTT